Abstract: Demand response methodologies for primary frequency response (PFR) for under or over frequency events. Aspects of the present disclosure include methods for controlling a fleet of distributed energy resources equipped for PFR and quantifying in real time an amount of primary frequency control capacity available in the fleet. In some examples, the DERs may be configured to consume and discharge electrical energy in discrete energy packets and be equipped with a frequency response local control law that causes each DER to independently and instantaneously interrupt an energy packet in response to local frequency measurements indicating a grid disturbance event has occurred.

Abstract: Disclosed are engineered multicellular organisms. The disclosed organisms comprise an aggregate of ciliated cells, and the organisms move when the ciliated cells are actuated. The engineered multicellular organisms also are capable of kinematic self-replication. The engineered multicellular organisms are capable of moving a plurality of dissociated ciliated cells into piles of ciliated cells which form a multicellular organism comprising an aggregate of ciliated cells which moves when the ciliated cells are actuated. Also disclosed are systems and methods for designing, preparing, and utilizing the engineered multicellular organisms.

Abstract: A method for preventing unauthorized access to information in a semiconductor device that is secured with a security protocol that uses a first portion of the information may include in response to a verified inaccessibility-inducing signal, unlocking safety lock circuitry which is operable to prevent unintentional activation of self-destruction in the semiconductor device, and initiating the self-destruction of at least a portion of the semiconductor device. A semiconductor device is configured to prevent unauthorized access to information available therein that is secured with a security protocol that uses a first portion of the information. The semiconductor device may include safety lock circuitry operable to prevent unintentional activation of self-destruction in the semiconductor device and control circuitry operable to unlock the safety lock circuitry and to initiate the self-destruction of at least a portion of the semiconductor device in response to a verified inaccessibility-inducing signal.

Abstract: An engineered polypeptide includes at least two units, wherein each unit includes a polypeptide of SEQ ID NO: 4, a polypeptide of SEQ ID NO: 5, a polypeptide with 90% or greater homology to SEQ ID NO: 4, or a polypeptide with 90% or greater homology to SEQ ID NO: 5, wherein the engineered polypeptide does not comprise SEQ ID NO: 12 or SEQ ID NO: 13. Further described is a synthetic materials including the peptides. Also included are synthetic materials including polypeptide of any one of SEQ ID NOs: 9-32, a polypeptide with 90% or greater homology any one of SEQ ID NOs: 9-32, a polypeptide encoded by any one of SEQ ID NOs. 57-79, or a polypeptide with 90% or greater homology to a polypeptide encoded by any one of SEQ ID NOs. 57-79.

Abstract: Disclosed herein are systems and uses of systems operating between fully quantum coherent and fully classical states. Examples include a hybrid quantum-classical computing system comprising a plurality of quantum processors connected via classical means.

Abstract: Techniques for diagnosing a patient having an AAA. The techniques include using a computer hardware processor to perform: accessing computed tomography angiography (CTA) images of a portion of the patient, the portion of the patient including the AAA of the patient; providing the CTA images as input to a trained machine learning model, the trained machine learning model being configured to classify a property of the AAA based on the CTA images; and determining, based on the classified property of the AAA, a diagnosis of the patient, the diagnosis including information identifying at least one condition (e.g., an endoleak, an AAA rupture) of the patient.

Abstract: The present invention, in some aspects, relates to systems and methods for determining oxidized proteins, including glutathionylated proteins such as S-glutathionylated proteins. The systems and methods of the invention can be used in vitro (e.g., in cell or tissue culture) or in vivo, for example, to diagnose a person having an oxidative stress condition. For instance, in some cases, the invention can be used to spatially determine the location and/or concentration of oxidized proteins within cells and/or tissues (e.g., through visual detection).

Abstract: The disclosure relates to compounds that demonstrate efficacy in blocking PACAP receptors (e.g. PAC1) and associated methods of treating neurological diseases or disorders using the disclosed compounds. The neurological diseases or disorders include, but are not limited to, stress-related diseases (e.g. chronic stress, post-traumatic stress disorder (PTSD), panic disorder, anxiety, or general anxiety disorder), pain-related diseases (e.g. chronic pain, primary headache disorders, or migraines), or addiction (e.g. addiction to a substance (e.g. addiction to cocaine, amphetamines, methamphetamine, methylphenidate, nicotine, alcohol, prescription medication, marijuana, tobacco, or an opioid selected from heroin, fentanyl, codeine, hydrocodone, morphine, oxycodone, hydromorphone, and methadone)).

Abstract: The present invention has to do with a method and system for peritoneal dialysis catheter weighted anchors. The peritoneal dialysis catheter weighted anchors can be inserted and retrieved using standard techniques and available insertion/retrieval systems. The peritoneal dialysis catheter weighted anchors can be attached and secured to all types of PD catheters as an ancillary anchor device.

Abstract: A membrane filtration cell is provided which includes a fluid passageway and a filtration membrane positioned within the passageway, the filtration membrane dividing the fluid passageway into two chambers, a retentate chamber and a permeate chamber. A first electrode is positioned in the retentate chamber and a second electrode is positioned in the permeate chamber, where the first electrode and the second electrode are configured to apply an electric field across the filtration membrane. The membrane filtration cell also includes an acoustic device configured to apply an acoustic field across the retentate chamber, where the synergistic combination of the electric field and the acoustic field prevents fouling on the filtration membrane.

Abstract: Described herein are antibodies or variants thereof that specifically bind to coronavirus antigens, such as SARS-CoV-2 antigens. The antibodies can be neutralizing antibodies. Also provided are methods of using the antibodies, including methods of treating a subject infected with SARS-CoV-2, and methods of diagnosing a subject infected with SARS-CoV-2.

Abstract: Described herein are antibodies or variants thereof that specifically bind to coronavirus antigens, such as SARS-CoV-2 antigens. The antibodies can be neutralizing antibodies. Also provided are methods of using the antibodies, including methods of treating a subject infected with SARS-CoV-2, and methods of diagnosing a subject infected with SARS-CoV-2.

Abstract: The present invention has to do with a method and system for preformed peritoneal dialysis (PD) catheter weighted anchors. The peritoneal dialysis catheter weighted anchors can be inserted and retrieved using standard techniques and available insertion/retrieval systems. The peritoneal dialysis catheter weighted anchors can be attached and secured to all types of PD catheters as an ancillary anchor device.

Abstract: The invention features isolated protein complexes and compositions and methods for use thereof. In embodiments, the isolated protein complexes are used for treating conditions associated with reperfusion injury, hypofusion, and/or low/no-reflow. The isolated protein complexes comprise a fusion protein complexed with basic fibroblast growth factor (FGF2), hepatocyte growth factor (HGF), or vascular endothelial growth factor (VEGF). The fusion protein contains an immunoglobulin G (IgG) Fc domain fused to a polypeptide (e.g., Jagged1, a growth factor, or a cytokine).

Abstract: Catheters, systems, and related methods for optimized for mapping, minimizing, and treating cardiac fibrillation in a patient, including an array of at least one stacked electrode pair, each electrode pair including a first electrode and a second electrode, wherein each electrode pair is configured to be orthogonal to a surface of a cardiac tissue substrate, wherein each first electrode is in contact with the surface to record a first signal, and wherein each second electrode is separated from the first electrode by a distance which enables the second electrode to record a second signal, wherein the catheter is configured to obtain one or more measurements from at least a first signal and a second signal in response to electrical activity in the cardiac tissue substrate indicative of a number of electrical circuit cores and distribution of the electrical circuit cores for a duration across the cardiac tissue substrate.

Abstract: According to some aspects, a cardiac pacemaker for implantation within a subject is provided, the pacemaker including a housing, at least one sensor configured to detect an activity level of the subject, and at least one processor coupled to the sensor configured to detect inactivity of the subject based on output from the at least one sensor, produce a first signal configured to increase the heart rate of the subject to a first heart rate during a first time period, wherein the first heart rate is above a resting heart rate and below 100 beats per minute, and in response to determining that the first time period has elapsed, producing a second signal configured to increase the heart rate of the subject to a second heart rate during a second time period, wherein the second heart rate is between 100 and 140 beats per minute.

Abstract: The invention features methods and compositions for treating a reperfusion injury, hypofusion, ischemic injury, and/or low/no-reflow. In embodiments, the compositions contain complexes containing a basic fibroblast growth factor (FGF2) and an immunoglobulin G (IgG) polypeptide, or fragments thereof. In embodiments, the complexes further contain a hepatocyte growth factor (HGF) polypeptide, a vascular endothelial growth factor (VEGF) polypeptide, or fragments thereof.

Abstract: Compositions and methods involving protein disulfide isomerase (PDI) inhibitors, such as protein disulfide isomerase A3 (PDIA3) inhibitory compounds, for human coronavirus, such as severe acute respiratory syndrome (SARS) virus (e.g., SARS-CoV-2), therapies are disclosed herein.

Abstract: The present invention generally relates to systems and methods for treating certain oxidative stress conditions. In one aspect, compositions and methods of the invention can be used to treat a subject having an oxidative stress condition, for example, a subject having pulmonary fibrosis. In some embodiments, an inhibitor of ERp57 (for example, thiomuscimol) and/or an inhibitor of GSTP (for example, TLK-199) may be used to treat the subject. Also provided in certain aspects of the present invention are kits for such therapies, methods for promoting such therapies, and the like.

Abstract: Demand response methodologies for primary frequency response (PFR) for under or over frequency events. Aspects of the present disclosure include methods for controlling a fleet of distributed energy resources equipped for PFR and quantifying in real time an amount of primary frequency control capacity available in the fleet. In some examples, the DERs may be configured to consume and discharge electrical energy in discrete energy packets and be equipped with a frequency response local control law that causes each DER to independently and instantaneously interrupt an energy packet in response to local frequency measurements indicating a grid disturbance event has occurred.